Screener / SEC EDGAR /CIK 0001717115 /10-K filed Feb 24, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Internet & Software Services

Tempus AI, Inc. TEM

Compare with peers Embed
The 10-K against last year's

278 changes: 65 added, 54 removed, 157 reworded, 2 quiet changes

10-K Feb 24, 2026 vs Feb 24, 2025

10-K 0001193125-26-066961 (Feb 24, 2026) vs 10-K 0000950170-25-025603 (Feb 24, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

591 paragraphs · 32 new · 185 reworded · 34 gone · 10-K Feb 24, 2026 against Feb 24, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 268 · 48% changed Every version of it
In addition, we use AI, including generative AI, and machine learning technologies in our products and services . services. The development and use of AI/machine learning present various privacy and security risks that may impact our business. AI/machine learning are subject to privacy and data security laws, as well as increasing regulation and scrutiny. Several jurisdictions around the globe, including Europe and certain U.S. states, have proposed enacted, or are considering laws governing the development and use of AI/machine learning, such as the EU’s AI Act. We expect other jurisdictions will adopt similar laws. Additionally, certain privacy laws extend rights to consumers (such as Act, the right to delete certain personal data) Colorado Artificial Intelligence Act, California Bot Disclosure Law, the Utah Artificial Intelligence Policy Act, and regulate the CCPA regulations on automated decision making, which may be incompatible with our use of AI/machine learning. These obligations may make it harder for us to conduct our business using AI/machine learning, lead to regulatory fines or penalties, require us to change our business practices, retrain our AI/machine learning, or prevent or limit our use of AI/machine learning. decision-making technology. For example, the FTC has required other EU AI Act sets out a risk-based framework, subjecting certain AI technologies to numerous compliance obligations, including transparency, conformity and risk assessment, monitoring and human oversight requirements. Under the EU AI Act, non-compliant companies to turn over (or disgorge) valuable insights or trainings generated through the use of AI/machine learning where they allege the company has violated privacy and consumer protection laws. If we cannot use AI/machine learning or that use is restricted, our business may be less efficient, subject to administrative fines of up to 35 million Euros or we may be at 7% of a competitive disadvantage. company’s total worldwide
Paragraph 34 · 48% changed Every version of it
We believe our commercial success is dependent upon our ability to continue to successfully market and sell our current Genomic diagnostics products to continue to grow our Data business by expanding our current relationships and developing new relationships with clinicians and pharmaceutical and biotechnology customers, and to develop and commercialize new products based on our Platform, including by expanding our Genomics product line to new disease areas and by advancing our existing and future AI Applications. line. Our ability to achieve and maintain sufficient commercial market acceptance of our existing and future products will depend on a number of factors, including:
Paragraph 522 · 48% changed Every version of it
These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute such action in other jurisdictions, all of which could seriously harm our business, financial condition condition, and results of operations.
Paragraph 182 · 47% changed Every version of it
Our estimates of the annual total addressable markets for our current products and products under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients profiled with genomic diagnostics in the diseases we test, the assumed prices for genomic and algorithmic testing products, the number of genomic and algorithmic tests that we are able to successfully develop and commercialize, and the existing market for multimodal patient data and clinical trial matching services. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell our products, the number of genomic or algorithmic tests we are able to successfully develop and commercialize, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business, financial condition and results of operations.
Paragraph 290 · 46% changed Every version of it
The FDA has historically operated under a policy of enforcement discretion with respect to LDTs whereby the FDA did not actively enforce its regulatory requirements for such tests. On May 6, 2024, the FDA published final regulations that took effect on July 5, 2024 that will 2024, and which attempted to phase-out enforcement discretion over a period of four years and require required compliance with device registration and listing requirements, medical device reporting requirements, 510(k) clearance, denovo authorization or Premarket Approval and the requirements of the FDA’s Quality System Regulation. If we fail to phase-in our compliance with these regulations we may be required to stop selling our existing tests or launching any other tests we may develop In March 2025, however, a federal district court in the Northern District of Texas vacated and to conduct additional clinical trials or take other actions prior to continuing to market our tests. This could significantly increase set aside the costs and expenses of conducting, or otherwise harm, our business, financial condition and results of operations. Even if such tests are authorized for marketing by FDA’s final rule, which effectively ended the FDA, the agency could limit the test’s indications for use, which may significantly limit the market for that product and may adversely affect our business and financial condition. Additionally, because our Platform and other software applications we make available include functionality related to the reporting of results from the LDTs we run, the FDA could FDA’s attempt to regulate such diagnostic tests as medical devices and called into question the software applications, including portions agency’s long-standing policy of enforcement discretion with respect to LDT’s. It is unclear whether this or future administrations will attempt to reinstitute such policies, or how the changing regulatory regime might impact our Platform, that we utilize to provide results of the LDTs to our customers and this may require costly modifications, additional development or the reduction in functionality in our offerings which could, in turn, make them less attractive to our customers. business.
Paragraph 91 · 46% changed Every version of it
We have limited commercialized algorithms within our AI Applications product line. Revenue generated from AI Applications is reported within our Data and Services applications product line and was $20.2 million, $12.4 million and $5.5 million for the years ended December 31, 2025, 2024 and 2023, respectively, which represents 1.6%, 1.8% and 1.0% of our total revenue in each period. We have a number of additional Algos algorithms in development and we may not be successful in developing and commercializing these or future Algos, or in attaining our other development targets. Further, the scope and robustness of the AI Applications that we can offer our customers depend significantly on the continued success of our Genomics product line and access to third-party data, of which there can be no assurance. We also cannot accurately estimate how our future AI Applications will be priced, whether reimbursement can be obtained or whether we will generate any revenue from such AI Applications. Further, the use of diagnostics that are entirely algorithmic in nature is novel and today represents only a small proportion of the diagnostics market. The use of algorithmic diagnostics may also be subject to existing and entirely new regulations that may substantially impact their adoption, use, reimbursement and ongoing viability. While we believe AI Applications represent a significant long-term opportunity for us, there can be no assurances that a robust and sustained market for such diagnostics will develop or that we will successfully compete in any such market.
Paragraph 137 · 46% changed Every version of it
Each payer makes its own decision as to whether to provide coverage for our tests, whether to enter into a contract with us and the reimbursement rate for a test. Negotiating with payers is time-consuming, and payers often insist on their standard form contracts, which may allow payers to terminate coverage on short notice, impose significant obligations on us and create additional regulatory and compliance hurdles for us. There can be no guarantee that a payer will provide adequate coverage or reimbursement for our tests or that we can reach an agreement with the payer on reasonable terms without being subject to additional regulatory and compliance risks. In cases where there is no coverage, or we do not have a contracted rate for reimbursement with the payer, the patient is typically responsible for a greater share of the cost of the test, which may result in delay of revenue, increase collection costs or decrease the likelihood of collection. We maintain a financial assistance program under which we assess patient financial need and offer discounted or no-cost tests to certain patients who meet the financial and other eligibility criteria of the program. This may result in scrutiny by payers of our financial assistance program and could result in recoupment actions or termination of coverage of our tests.
Paragraph 128 · 45% changed Every version of it
As we commercialize additional Genomics Diagnostics products, we will need to incorporate new equipment, implement new technology systems and laboratory processes, and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business.

MD&A

137 paragraphs · 33 new · 64 reworded · 20 gone · 10-K Feb 24, 2026 against Feb 24, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 109 · 50% changed
The Through December 31, 2025, we repaid in full the principal amount of the Term Loan Facility for $276.9 million, leaving only the Additional Term Loan Facility and the Revolving Credit Facility mature on February 3, 2030. The Term Loan Facility matures in September 2027. as outstanding.
Paragraph 84 · 47% changed
(3)Acquisition (2)Acquisition related expenses consist of legal legal, diligence, accounting, and diligence costs financing costs, as well as a gain on bargain purchase, incurred for the acquisition of Ambry acquisitions during the year years ended December 31, 2024, 2025 and for the acquisitions of Mpirik, Inc. and SEngine Precision Medicine LLC during the year ended December 31, 2023. 2024.
Paragraph 67 · 46% changed
The increase change in Interest expense Loss on debt extinguishment for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, was primarily driven by compounding interest on our Amended Note and additional debt entered into under our the repayment of the Term Loan Facility Facility, which includes repayment of the principal, accrued interest, and prepayment premium. The repayment resulted in April and October 2023. a loss on debt extinguishment of $12.0 million.
Paragraph 50 · 43% changed
The increase in Genomics revenue for the year ended December 31, 2024, compared Hereditary tests increased to the same period in 2023, was primarily due to an increase in the number of oncology NGS tests, which increased from approximately 218,700 460,500 tests for the year ended December 31, 2023 2025 due to approximately 270,800 tests for the year ended December 31, 2024. Additionally, there was acquisition of Ambry in February 2025 and resulted in an increase of $362.7 million in average revenue per NGS oncology test, which increased from approximately $1,450 per test for the year ended December 31, 2023 to approximately $1,510 per test for the year ended December 31, 2024. The increase in average revenue per test was driven primarily by increased Medicare reimbursement rates. The increase in the number of oncology NGS tests and average revenue per NGS oncology test resulted in a $91.8 million increase in Genomics Diagnostics revenue.
Paragraph 102 · 41% changed
On September 22, 2022, February 3, 2025, we entered into a Credit Third Amendment Agreement, or the Credit Agreement, with Ares Third Amendment Agreement which, among other things, provided for a an additional $200.0 million tranche of senior secured loan, term loans, or the Additional Term Loan Facility, and together with the Term Loan Facility, the Term Loans, and $100.0 million in priority revolving loan commitments, or the Revolving Credit Facility, and loans thereunder, the Revolving Loans. We received $194.0 million under the Additional Term Loan Facility, which is the aggregate principal amount of $175 $200.0 million, less original issue discount of $4.4 $4.0 million and deferred financing $2.0 million in legal fees of $2.6 million. On April 25, 2023, we entered into an amendment paid to third parties, and $97.1 million in revolving loans under the Revolving Credit Agreement, Facility, which increased is the aggregate principal amount of the Term Loan Facility by an additional $50 $100.0 million, less original issue discount of $1.3 million, $2.0 million and increased $0.9 million in legal fees paid to third parties, the interest rate on proceeds of which were used to fund the Term Loan Facility by 25 basis points. On October 11, 2023, we entered into a second amendment to the Credit Agreement, which increased the aggregate principal amount of the Term Loan Facility by an additional $35 million, less original issue discount of $0.9 million. On February 3, 2025, in connection with the closing of the Acquisition, we entered into a third amendment to the Credit Agreement providing cash consideration for the Ambry Acquisition and to pay related fees. The Third Amendment Agreement was accounted for as a debt modification. The Additional Term Loan Facility of $200.0 million (together with the Term Loan Facility, the “Term Loan Facilities” and the Loans issued thereunder, the “Term Loans”) and the Revolving Credit Facility of $100.0 million (and the Loans thereunder, the Revolving Loans). mature on February 3, 2030.
Paragraph 87 · 40% changed
We have funded our operations to date principally from the sale of stock, convertible debt, term debt, the Revolving Credit Facility, and sales of our products. As of December 31, 2024, 2025, we had cash, cash equivalents and restricted cash of $341.8 $609.5 million. In April 2024, we sold an aggregate of 3,489,981 shares of our Series G-5 convertible preferred stock at a price per share of $57.3069, for an aggregate purchase price of approximately $200.0 million in a private placement to an accredited investor. In June 2024, we completed our IPO, which resulted in net proceeds of $382.0 million after deducting underwriting discounts and commissions of $28.7 million.
Paragraph 115 · 39% changed
Cash used in operating activities during the year ended December 31, 2024 2025 was $189.0 $218.1 million, which resulted from a net loss of $705.8 $245.0 million and a net change in our operating assets and liabilities of $37.8 $178.5 million, offset by non-cash charges of $554.6 $205.5 million. Non-cash charges primarily consisted of $534.1 $124.7 million of stock-based compensation, a $42.4 million increase in the fair value of the warrant liability, and $37.2 $102.3 million of depreciation and amortization, $12.0 million loss on debt extinguishment, $11.6 million of non-cash operating lease costs and $10.5 million of PIK interest added to principal, offset by deferred income taxes of $52.7 million, and $16.5 million of gain on marketable equity securities. The net change in our operating assets and liabilities was primarily the result of a gain $90.4 million increase in accounts receivable due to increased sales and the timing of $39.1 customer payments, a $25.0 million increase in related party asset, due to future services to be provided by Pathos under the Pathos Master Agreement, a $17.3 million increase in investments and other assets, a $16.0 million decrease in deferred other income related to the IP License Agreement with SB Tempus, and a $7.2 million decrease in accounts payable, due to timing of payments.
Paragraph 31 · 38% changed
Genomics Diagnostics primarily includes revenue from Oncology testing (legacy Tempus) and Hereditary testing (legacy Ambry Genetics). Oncology testing includes revenue from diagnostics, PCR profiling, and other anatomic and molecular pathology testing to healthcare providers, oncologists, pharmaceutical companies, biotechnology companies, researchers, and other third parties. Hereditary testing includes revenue from inherited cancer risk, whole exome and genome profiling for rare conditions, and all other inherited screening testing primarily to genetic counselors.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors289 words changed in this paragraph; it is 37% similar to last year's version.
In addition, to finance any acquisitions, joint ventures or investments, we have in the past, and may in the future choose to issue shares of our Class A common stock as consideration, which would dilute the ownership of our stockholders. For example, on November 4, 2024 in February 2025, we entered into a Securities Purchase Agreement, or completed the Purchase Agreement, with REALM IDx, Inc., a Delaware corporation, or the Seller, and the Seller’s ultimate parent, Konica Minolta, Inc., a Japanese corporation, as guarantor, acquisition of Ambry pursuant to which we agreed to purchase all of the outstanding shares of capital stock of Ambry. Such transaction is hereinafter referred to as the Acquisition. Pursuant to the terms of the Purchase Agreement, consideration for the Acquisition consisted of $375.0 million in cash, subject to adjustment for cash, unpaid indebtedness, unpaid transaction expenses and net working capital of Ambry, or Cash Consideration, plus issued an aggregate of 4,483,136 shares of our Class A common stock, or and in August 2025, we completed the Stock Consideration, all acquisition of Paige AI, Inc., pursuant to which we issued an aggregate of 1,256,977 shares were issued by us to the Seller on February 3, 2025, upon the closing of the Acquisition, and 2,152,505 of which shares are subject to a lock-up for a period of one year following the closing date of the Acquisition. In connection with the Acquisition, we entered into an amendment to the Credit Agreement providing for the Additional Term Loan Facility and the Revolving Credit Facility. We utilized borrowings under the Additional Term Loan Facility and the Revolving Credit Facility to fund the Cash Consideration for the Acquisition and to pay fees and expenses related thereto. For future acquisitions, joint ventures or investments, there can be no assurance that additional funds will be available on terms that are favorable to us, or at all. Class A common stock. If the price of Class A our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration. In addition, we have in the past utilized, and may in the future utilize borrowings under the Credit Facilities to fund the cash consideration for acquisitions

Source: Item 1A, 10-K 0001193125-26-066961 vs Item 1A, 10-K 0000950170-25-025603

MD&A259 words changed in this paragraph; it is 39% similar to last year's version.
Through The Term Loans are subject to quarterly interest payments, which bears interest based on Term SOFR. Additionally, we may make either a paid-in-kind, or PIK, election or a Cash election. Pursuant to the Original Credit Agreement, as amended by the Fourth Amendment Agreement, or the Credit Agreement, through December 31, 2025, interest on the Term Loans accrues at a per annum rate as follows: (i) for any interest period for which we elect to pay interest in cash, the cash interest rate for Base Rate and Term SOFR borrowings will be the Base Rate plus 6.25% and Term SOFR plus 7.25%, respectively, and (ii) for any interest period for which we elect to pay interest in kind, the cash interest rate for Base Rate and Term SOFR borrowings will be the Base Rate plus 4% and Term SOFR plus 5%, respectively, and the paid-in-kind PIK interest rate will be 3.25%. From and after January 1, 2026, interest on the Term Loans accrues at a per annum rate as follows: (i) for any interest period for which we elect to pay interest in cash, the cash interest rate for Base Rate and Term SOFR borrowings will be the Base Rate plus a margin ranging from 5.75% to 6.75% and Term SOFR plus a margin ranging from 6.75% to 7.75%, respectively, and (ii) for any interest period for which we elect to pay interest in kind, the cash interest rate for Base Rate and Term SOFR borrowings will be the Base Rate plus a margin of 4% or 4.5% and Term SOFR plus a margin of 5% or 5.5%, respectively, and the paid-in-kind interest rate will be 3.25%. The applicable margin for any interest period for which we elect to pay interest in cash will be based on our consolidated first lien leverage ratio and whether the Company has satisfied certain junior capital raising requirements. The applicable margin for any interest period for which we elect to pay interest in kind will be based on whether we have satisfied certain junior capital raising requirements.

Source: Item 7, 10-K 0001193125-26-066961 vs Item 7, 10-K 0000950170-25-025603

Accounting Policies128 words changed in this paragraph; it is 73% similar to last year's version.
For clinical orders from Medicare, Medicaid, and commercial insurance, the Company determines transaction price by reducing the standard charge by the estimated effects of any variable consideration, such as contractual allowance and implicit price concessions. The Company estimates the variable consideration using the expected value method which is based on historical collections in relation to established rates, as well as known current or anticipated reimbursement trends not reflected in the historical data. The Company uses significant judgment when assessing whether estimates of variable consideration are constrained and these estimates are calculated based upon both insurance payor-specific and aggregated factors that include historical billing and adjustment data. Estimates are inclusive of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. The occur.The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. During the year ended December 31, 2023, the Company recognized $12.2 million from cash collections in excess of revenue recognized in prior years, primarily as a result of achieving a higher success rate on appeals than estimated. During the year years ended December 31, 2025 and 2024, the amount recognized from cash collections in excess of revenue recognized in prior years was not material. Payment is typically due after the claim has been processed by the payer, generally 30-120 days from date of service. While management believes that the estimates are accurate, actual results could differ and the potential impact on the financial statements could be significant. The Company recognized revenue for clinical orders of $884.5 million, $409.4 million, $328.4 million and $157.2 $328.4 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001193125-26-066961 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000950170-25-025603

Legal Proceedings77 words changed in this paragraph; it is 63% similar to last year's version.
On June 11, 2024, Guardant Health Inc., or Guardant, filed a complaint against us in the U.S. District Court for the District of Delaware. The complaint alleges that the Tempus xF, Tempus xF+, Tempus xM Monitor and Tempus xM MRD products use liquid biopsy technology that infringes five Guardant U.S. patents. The complaint seeks injunctive relief, unspecified monetary damages (including enhanced damages), a future mandatory royalty, costs and attorneys fees. On January 17, 2025, Guardant separately sought a Declaratory Judgment against Tempus in the U.S. District Court for the District of Delaware regarding the veracity of certain advertisements Guardant has published regarding the companies’ respective products. On March 14, 2025, Tempus filed multiple counterclaims against Guardant under the Lanham Act and related states statutes alleging, among other things, that Guardant’s advertisements were false and misleading. Tempus filed a separate patent infringement complaint against

Source: Item 3, 10-K 0001193125-26-066961 vs Item 3, 10-K 0000950170-25-025603

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of TEM's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 24, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Genetic testing has raised ethical, legal and social issues regarding privacy rights and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, hereditary tests even if permissible; they may also refuse genetic testing due to concerns regarding eligibility for life or other insurance. Ethical and social concerns may also influence U.S. and foreign patent offices and courts with regard to patent protection for technology relevant to our business. These and other ethical, legal and social concerns may limit market acceptance of our tests or reduce the potential markets for our tests, either of which could have an adverse effect on our business, financial condition or results of operations.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered next-generation sequencing tests under the NGS NCD. An NGS test is typically not covered by Medicare when cancer patients do not have the above-noted indications for cancer under either an NCD or LCD.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•Agentic AI is a type of AI that can function independently to actively achieve specific outcomes with limited human involvement through pre-programmed planning, reasoning, and decision execution.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
In April 2025, we entered into expanded multi-year strategic collaborations with AstraZeneca and Pathos for the development of a foundation model in the field of oncology. Under this collaboration, we will work together with AstraZeneca and Pathos to build the foundation model, which will incorporate our multi-modal de-identified oncology data, and once complete, the model will be shared among all three parties to advance their individual efforts to improve patient care. The development and deployment of foundation models could ultimately reduce demand for our Data and applications products, as once a company is able to utilize a foundation model to advance its business objectives, it may no longer have a need to license our de-identified data. Any significant decrease in the demand for, or value of, our Data and applications products would have a material adverse effect on our financial condition and results of operations. Also, there is no guarantee that our development efforts will be successful, or that the foundation model will achieve its intended purpose.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•in the event the conditional conversion feature of the Notes is triggered, requiring us under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than a long-term liability, which would result in a material reduction of our net working capital; and
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
application of consumer, health-related, and data protection laws, especially with respect to genetic samples and data, in the United States, the EU (including all countries in the EEA), and elsewhere are often uncertain, contradictory, and in flux.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Since its enactment, there have been efforts to repeal, replace, and amend all or part of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law, which is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. The OBBBA also narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits, that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. Congress is also considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies. It is unclear how any additional healthcare reform measures will impact the ACA and our business.
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 66
AddedRisk Factors
The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at the Department of Health and Human Services, the FDA, CMS and related agencies. Such actions and policies may, among other things, significantly reduce U.S. medical device prices, potentially impacting manufacturers’ global pricing strategies and profitability, while increasing their operational costs and compliance risks.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Our Notes and the issuance of shares of our Class A common stock upon conversion of the Notes, if any, may impact our financial results, result in dilution to our stockholders, create downward pressure on the price of our Class A common stock, and restrict our ability to raise additional capital or to engage in a beneficial takeover.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
•servicing our debt requires a certain level of cash flow or financing from other sources, and our ability to make scheduled payments of the principal and interest, or to refinance or repurchase our Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control;
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
•We previously identified a material weakness in our internal control over financial reporting. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
The life sciences scientific community is comprised of a small number of early adopters and key opinion leaders who significantly influence the rest of the community. The success of life sciences products is due, in large part, to acceptance by the scientific community and their adoption of certain products as best practice in the applicable field of research. The current
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
On February 10, 2022, the Local MAC issued a revised LCD (L37810), and a corresponding Billing and Coding update (A56867). The increased scope of coverage provided for in the revised LCD will result in the CPT code they instructed us to begin billing in July 2021 being reimbursed at the prevailing Medicare rate for those tests which meet the revised coverage criteria. The modified LCD is effective April 1, 2022 and applies to genomic sequence analysis panel tests in the treatment of solid tumors, which primarily impacts our solid tumor assay, xT, given the modified scope of coverage in the revised LCD.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Beginning January 1, 2023, a new CPT code went into effect covering full transcriptome testing when performed separately from DNA testing. Historically, our xT assay was actually comprised of two separate and distinct procedures, DNA and RNA. Given there was not an applicable CPT code for RNA, we did not bill that test. With the introduction of the new code, we now have two separate assays, one analyzing DNA – xT and one analyzing RNA – xR that are ordered and billed for separately. We requested that the Local MAC add the new CPT code to the LCD, which they did effective January 1, 2023.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Furthermore, on September 27, 2023, the Centers for Medicare and Medicaid Services (CMS) published calendar year 2024 preliminary payment determinations for new and reconsidered codes on the Medicare clinical laboratory fee schedule (CLFS), including new codes that may apply to tests we offer through our Genomics business. In doing so, CMS rejected the recommendations from experts on the Clinical Diagnostic Laboratory Test (CDLT) Advisory Panel and recommended reimbursement rates for several new procedure codes describing genomic profiling tests that are substantially below our costs to perform them. Following a comment period, CMS revised its preliminary determination and assigned each of the new codes to gapfill – a process by which each of the individual MACs prices the codes and the resulting median price across the MACs becomes the price on the Medicare CLFS. We are currently participating in the gapfill process with the MACs with which we operate. On May 1, 2024, CMS posted the MAC-specific payment recommendations which indicated that the codes applicable to our tests would be reimbursed at the same or a higher level than they were previously reimbursed. These recommendations were finalized in September and became effective January 1, 2024.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
sales. As a result, in the event a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
Penalties for violations of these laws vary. For instance, a single breach incident can result in findings of violations of multiple HIPAA provisions. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties, including imprisonment and/or additional fines. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face additional fines and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer, or use identifiable health information for commercial advantage, personal gain, or malicious harm. In addition, any allegation that we have violated HIPAA, regardless of its merit, could harm our reputation and consume significant internal resources. Responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
We are also subject to new laws governing the privacy of consumer health data. For example, Washington’s My Health My Data Act broadly defines consumer health data, places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Other states are considering and may adopt similar laws.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
increasingly scrutinizing certain personal data transfers and have proposed and may enact certain data localization requirements, for example, the Biden Administration’s executive order Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedRisk Factors
number of whom may receive stock or stock options as compensation for services provided, do not comply with current or future corporate practice of medicine statutes, regulations, agency guidance or case law.
Read it in 10-K Feb 24, 2025 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, we had indebtedness of $440.6 million, comprised of $168.2 $1.3 billion, comprising (i) $208.7 million under the convertible promissory note, as amended, or the Second Amended Note, that we issued to Google LLC, or Google, and $272.4 (ii) $206.0 million of senior secured term loans, or the Additional Term Loan Facility, and $100.0 million in priority revolving loan commitments, or the Revolving Credit Facility, pursuant to a credit agreement, or as amended, the Credit Agreement, with affiliates of Ares Capital Corporation, or Ares. Ares and (iii) $750.0 million of 0.75% Convertible Senior Notes due 2030, or the Notes, Our current and future indebtedness may have significant negative effects on our operations, including:
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Any disputes over appropriate coding, or requirements that we submit claims under codes with lower reimbursement rates, may materially adversely affect our business financial condition and results of operations,Use of coding for billing our products that does not describe a specific test, requires the claim to be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of medical necessity from the ordering physician. operations.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Further, on July 12, 2024, the AI Act was published in the Official Journal of the European Union and will follow a phased implementation process with the bulk of its requirements becoming currently scheduled to become applicable from August 2, 2026 (including 2026, including the core of the various requirements relevant to the “high-risk” AI systems referred to below). below (although, based upon certain targeted amendments suggested by the European Commission as part of its Digital Omnibus Regulation Proposal, the implementation date of such requirements may be delayed to a later date).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The Further, the use of diagnostics that are entirely algorithmic in nature is novel which (a) today represents only a small proportion of the diagnostics market (b) may also be subject to existing and entirely new regulations that may substantially impact their adoption, use, reimbursement and ongoing viability. viability, and (c) involves nascent billing and reimbursement policies, which could limit their adoption, use, and reimbursement.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Our use of generative AI tools may also present additional security risks because the generated source code may have been modeled from publicly available code, or otherwise not subject to all of our standard internal controls, which may make it easier for hackers and other third parties to determine how to breach our website and systems that rely on the code.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We currently sell our Genomics Diagnostics and AI Applications algorithmic diagnostic tests to clinicians healthcare providers and hospital systems in the United States through our own sales organization and may leverage distributors to help sell our Genomics diagnostic tests in international markets, and we sell our Data and Services products to pharmaceutical and biotechnology companies through our business development team.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We Due to the uncertainty in the regulatory framework, and the potential that other jurisdictions may decide to adopt similar or more restrictive legislation that may render the use of such technologies challenging, we may not be able to adequately anticipate or respond to these evolving laws and regulations, and we may need to expend additional resources to adjust our offerings in certain jurisdictions if applicable legal frameworks are inconsistent across jurisdictions.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If we fail A decision to phase-in our compliance with re-implement these regulations we may be required regulations, or the potential for congressional legislation governing laboratory developed tests, could cause us to stop selling our existing tests or launching any other tests we may develop develop, and to conduct additional clinical trials or take other actions prior to continuing to market our tests.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
It is possible that governmental authorities may conclude that our business practices, including our consulting and advisory board arrangements with physicians and other healthcare providers, a small number of whom may receive stock or stock options as compensation for services provided, do not comply with current or future corporate practice of medicine statutes, regulations, agency guidance or case law.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Despite our business development efforts, it could be difficult, expensive and/or time-consuming for healthcare providers to switch diagnostic tests for their patients, and our tests may not be widely accepted by those providers, if at all, which could in turn hinder the growth of sales of our tests.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Future or past business transactions (such as acquisitions or integrations) acquisitions, integrations, and other commercial relationships) could expose expose, and have exposed, us to additional privacy privacy, security and compliance risks, and we and the companies we have acquired these third parties have been, and may in the future, be future be, subject to litigation, regulatory investigations and other risks relating to privacy and security arising out of business transactions.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We are also dependent on the healthcare institutions within our network continuing to provide us with broad access to data to multimodal data to support the robustness of our Genomics Diagnostics tests and other offerings, as well as on establishing and maintaining our collaborations with ASCO, ONCare Alliance and similar organizations, and entering into similar collaborations third party organizations with other organizations in the future, access to large, multimodal datasets, particularly as we attempt to expand into other disease areas.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
We seek to ensure that all data and biological samples that we receive have been collected from patients, subjects or participants who have provided the necessary informed consent for purposes that extend to our development all associated activities.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On July 3, 2025, we completed a private offering, or the Offering, of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030, or the Notes, including the exercise in full of the initial purchasers’ option to purchase up to an additional $100.0 million principal amount of the Notes. The Notes are our general unsecured obligations and will mature on July 15, 2030, unless earlier converted, redeemed or repurchased. Interest on the Notes will accrue at a rate of 0.75% per year from July 3, 2025 and will be payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2026. Refer to Note 12 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further information regarding the issuance and terms of the Notes and the Capped Call transaction (each as defined below).
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Our net proceeds from the Offering were $725.7 million, after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by us. We used a portion of the net proceeds from the Offering to repay $293.5 million of the Term Loan Facilities (as defined below), which includes repayment of the principal, accrued interest, and prepayment premium and to pay approximately $41.8 million cost of the Capped Call. We expect to use the remaining net proceeds from the Offering for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses or technologies, working capital, operating expenses, capital expenditures and repayment of additional indebtedness.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On August 8, 2025, we entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Morgan Stanley & Co., LLC, Cantor Fitzgerald & Co., TD Securities (USA), LLC and Allen & Company LLC, as sales agents, or collectively, the Sales Agents, pursuant to which we may offer and sell from time to time, at our option, shares of Class A common stock through the Sales Agents, or the ATM. The issuance and sale, if any, of shares of Class A Common Stock under the Sales Agreement will be made pursuant to an automatically effective registration statement on Form S-3 and the related prospectus included therein, or the ATM Prospectus, which was filed with the SEC on August 8, 2025. In accordance with the terms of the Sales Agreement, under the ATM Prospectus, we may offer and sell shares of Class A common stock having an aggregate offering price of up to $500.0 million from time to time through the Sales Agents.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
For the year ended December 31, 2025, we sold 2,381,895 shares under the ATM at a weighted average price of $83.97 per share for total proceeds of $195.5 million, net of $4.5 million in commissions. In connection with the entry of the Sales Agreement and filing of the ATM prospectus, we incurred $0.9 million of deferred offering costs, of which $0.8 million was reclassified as a reduction of paid-in-capital upon completion of the sales that occurred in 2025. The remaining deferred offering
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
costs, which were incurred in anticipation of future ATM sales, are recorded in Prepaid and other assets on the consolidated balance sheet. As of December 31, 2025, approximately $300.0 million remained available for sale pursuant to the Sales Agreement and ATM Prospectus.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On August 22, 2025, or the Paige Closing Date, we completed our acquisition, or the Paige Acquisition, of Paige.AI, Inc., or Paige, a Delaware corporation, pursuant to an Agreement and Plan of Merger entered into on August 22, 2025 with Giant Panda Merger Sub, Inc., a Delaware corporation, Paige, and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the securityholder representative. Paige is an AI company specializing in digital pathology. The Paige Acquisition is expected to allow us to grow our dataset and establish a strong footprint in digital pathology with an industry leading technology portfolio.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
We acquired all of the issued and outstanding shares of Paige. The aggregate acquisition date fair value of consideration for the Paige Acquisition totaled $101.5 million. Consideration consisted of $3.0 million of cash and the issuance of an aggregate of 1,256,977 shares of our Class A common stock, or the Paige Stock Consideration, which was valued at $80.52 per share, the closing price of our Class A common stock on the Paige Closing Date. A portion of the Paige Stock Consideration was paid to employees as consideration for transaction bonuses. Paige will pay approximately $3.2 million to fulfill employee tax obligations related to the issuance, of which $3.0 million has been paid as of December 31, 2025. The equivalent was withheld from those employees in our Class A common stock and included in treasury stock. In accordance with the terms of the agreement, $6.9 million in equity consideration was held back and is payable within five business days of August 22, 2026. The net working capital adjustment resulted in a decrease to the acquisition price of $1.2 million which was recorded to goodwill.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In April 2025, we entered into a series of agreements with AstraZeneca AB, or AstraZeneca, and Pathos regarding both the development of a foundation large multimodal model in the field of oncology, or the Foundation Model, and the licensing of certain de-identified multi-modal data to assist in the development of the Foundation Model.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Specifically, we entered into a Statement of Work with AstraZeneca under the previously disclosed Master Services Agreement, dated November 17, 2021, as amended in October 2022, February 2023 and December 2023 (and as further amended from time to time, together with the Statement of Work, collectively referred to herein as the MSA). Pursuant to the MSA, (i) we will ensure that Pathos develops, and we provide AstraZeneca with, a Foundation Model which has been developed, validated, and maintained using de-identified datasets contributed by us, (ii) the Foundation Model will be developed, validated, and maintained by Pathos, (iii) AstraZeneca will pay us a fee of $35 million, and (iv) a syndicate of investors including AstraZeneca will contemporaneously execute a Stock Purchase Agreement with Pathos, or the SPA, as part of a preferred stock financing round of sufficient size given the obligations described herein.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
We also entered into an Order Form with Pathos under the previously disclosed Amended and Restated Master Agreement, restated effective February 12, 2024, (the Amended and Restated Master Agreement and the Order Form collectively referred to herein as the “Pathos Master Agreement”). Pursuant to the Pathos Master Agreement, (i) Pathos will be responsible for Foundation Model development activities under the MSA, (ii) we will license Pathos a comprehensive de-identified multi-modal dataset for the sole purpose of assisting in the development and training of the Foundation Model under the MSA, (iii) Pathos will pay us data license fees of $200 million over a three-year period, including an upfront payment of $50 million that has been paid as of April 2025 (iv) we will receive a license to use the Foundation Model upon its completion (with certain field restrictions and the right of sublicense to AstraZeneca), and (v) in consideration of Pathos’ commitments under the Pathos Master Agreement, we will pay Pathos $35 million, of which $25 million has been paid to date. Pathos, in its sole discretion, may pay up to 50% of the data license fees owed to us in shares of Pathos’ Series D Preferred Stock.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
A significant portion of our current Data and applications products sales are to customers in the life sciences industry, in particular the pharmaceutical and biotechnology industry. Demand for our Data and applications products could be affected by factors that adversely affect the life sciences industry, including macroeconomic and market conditions that may adversely impact earlier stage biotechnology companies such as substantial new tariffs and other restrictive trade policies.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Loss on debt extinguishment consists of the recognition of unamortized original issuance discount, unamortized deferred financing fees, and prepayment premium as a result of the prepayment of the Term Loan Facilities (defined in “—Liquidity and Capital Resources”).
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
On June 13, 2024, the registration statement relating to the initial public offering of our Class A common stock, or our IPO, was declared effective and shares of our Class A common stock began trading on the Nasdaq Global Select Market on June 14, 2024. On June 17, 2024, we completed our IPO in which we issued and sold 11,100,000 shares of Class A common stock, at a public offering price of $37.00 per share. We received net proceeds of $382.0 million after deducting underwriting discounts and commissions of $28.7 million.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
In connection with the closing of the IPO, all shares of our then-outstanding redeemable convertible preferred stock, other than our Series B redeemable convertible preferred stock, converted into an aggregate of 66,309,550 shares of Class A common stock. Series B redeemable convertible preferred stock converted on a one-for-one basis into an aggregate of 5,374,899 shares of Class B common stock. Subsequently, 331,110 shares of Class B common stock were automatically converted into shares of Class A common stock, such that there are 5,043,789 shares of Class B common stock outstanding. We issued an additional 236,719 shares of Class A common stock to an investor in Series G-3 preferred stock, pursuant to a separate agreement further described in Note 10.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
As of June 16, 2024, our redeemable convertible preferred stock had accrued $188.2 million of unpaid dividends, which were paid in 5,098,799 shares of Class A common stock at the closing of the IPO.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
The restricted stock units, or RSUs, granted to employees are subject to two vesting conditions. The first is a time-based component. The second vesting condition is the occurrence of a liquidity event. The liquidity event condition related to these awards was satisfied upon the effectiveness of the IPO. Upon effectiveness of the IPO, we recognized $488.3 million of stock-based compensation expense during the three months ended June 30, 2024. To meet the related tax withholding requirements, we withheld 1,911,316 shares of the 4,563,164 shares of Class A common stock issued. Based on the IPO public offering price of $37.00 per share, the tax withholding obligation was $70.8 million.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
In connection with the IPO, we amended and restated our certificate of incorporation, under which authorized capital stock consists of 1,000,000,000 shares of Class A common stock, 5,500,000 shares of Class B common stock, and 20,000,000 shares of preferred stock.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
Under the warrant, AstraZeneca had the right to purchase up to $100 million in shares of our Class A common stock at an exercise price equal to $37.00 per share, representing the public offering price in our IPO, or the IPO price. The warrant was exercisable through December 31, 2026. Under the terms of the warrant, AstraZeneca would be entitled to substantially the same registration rights with respect to the shares under the warrant as those granted to holders of registrable securities pursuant to our Ninth Amended and Restated Investors’ Rights Agreement, dated November 19, 2020. The warrant was automatically cancelled and terminated for no consideration as AstraZeneca declined to extend its financial commitment before December 31, 2024.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
year ended December 31, 2023. Additionally, there was a $16.3 million increase in Insights products due to the reversal of warrant contract asset amortization related to the termination of the warrant with AstraZeneca.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
(2)Settlement costs for the year ended December 31, 2023 include $0.2 million paid to settle a 2019 payment dispute and $8.5 million in costs accrued related to potential future settlements.
Read it in 10-K Feb 24, 2025 at sec.gov
RemovedMD&A
Our obligations under the Credit Agreement are guaranteed by certain of its subsidiaries and secured by substantially all of our and our subsidiaries’ assets. We have the right at any time and from time to time to prepay any of the Term Loans or Revolving Loans in whole or in part, subject, with respect to the Term Loans, to certain prepayment fees.
Read it in 10-K Feb 24, 2025 at sec.gov
RewordedMD&A
On February 3, 2025, in connection with the closing of the Acquisition, we entered into a third amendment to Third Amendment Agreement, or the Credit Third Amendment Agreement providing which, among other things, provided for an additional $200.0 million tranche of senior secured term loans, or the Additional Term Loan Facility of $200.0 million (together Facility, and together with the Term Loan Facility, the “Term Loan Facilities” Term Loans, and the Loans issued thereunder, the “Term Loans”) and $100.0 million in priority revolving loan commitments, or the Revolving Credit Facility of $100.0 million (and the Loans Facility, and loans thereunder, the Revolving Loans). Loans.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Net revenue Genomics Diagnostics $ 955,381 $ 451,749 $ 363,022 Data and services applications 316,408 241,649 168,800 Total net revenue $ 1,271,789 $ 693,398 $ 531,822 Cost and operating expenses Cost of revenues, genomics diagnostics 386,102 243,467 189,165 Cost of revenues, data and services applications 87,790 68,818 56,482 Technology research and development 146,107 167,519 95,155 Research and development 172,924 149,325 90,343 Selling, general and administrative 731,738 755,351 296,760 Total cost and operating expenses 1,524,661 1,384,480 727,905 Loss from operations $ (252,872) $ (691,082) $ (196,083) Interest income 12,628 11,084 7,601 Interest expense (70,267) (53,653) (46,869) Loss on debt extinguishment (12,034) — Other income, net 31,447 32,336 21,822 Loss before provision for benefit from (provision for) income taxes (291,098) (701,315) (213,529) Provision for Benefit from (provision for) income taxes 51,684 (266) (288) Losses from equity method investments (5,614) (4,228) (301) Net Loss $ (245,028) $ (705,809) $ (214,118)
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 (in thousands) Net loss $ (245,028) $ (705,809) $ (214,118) Interest income (12,628) (11,084) (7,601) Interest expense 70,267 53,653 46,869 Depreciation 32,054 26,356 21,279 Amortization 70,270 10,889 11,770 Provision (Benefit from) provision for income taxes (51,684) 266 288 EBITDA $ (136,749) $ (625,729) $ (141,513) Losses on from equity method investments 5,614 4,228 301 Fair value changes(1) (17,807) (27,868) (22,307) Stock-based compensation expense 124,747 534,138 — Employer payroll tax related to stock-based compensation 11,539 13,543 — Acquisition related expenses(2) 5,937 2,708 G-4 Special Payment — 2,250 — Amortization of technology license (15,955) (7,977) Franchise taxes related to IPO 1,647 — Settlement costs(2) Other tax expense 1,608 — 8,625 Acquisition related expenses(3) 2,708 672 Loss on debt extinguishment 12,034 — Adjusted EBITDA $ (7,385) $ (104,707) $ (154,222)
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase in Cost of revenues for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, was primarily due to an increase increases of $24.0 $115.0 million in material and service costs, $22.1 of which $69.2 million in material and services is due to the Ambry Acquisition, $41.4 million in personnel-related costs, of which $30.7 million is due to the Ambry Acquisition, $14.0 million in cloud costs, offset by a decrease of $12.8 million of stock-based compensation expense expenses related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO, $6.0 million IPO in personnel costs, and $4.2 million in cloud expenses. the prior period.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Cash used in investing activities during the year ended December 31, 2024 2025 was $130.4 $398.4 million, which was the result of a $95.2 $376.7 million investment in a joint venture in July 2024 (see Note cash paid related to the Ambry, Paige, Deep 6 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K), $36.2 million in purchases of marketable equity securities, and OneOme acquisitions, purchases of property and equipment of $22.1 $21.0 million, and $6.2 million of capitalized software costs from the Ambry Acquisition, offset by proceeds from the sale of marketable equity securities of $23.1 $8.3 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase in Cost of revenues revenues, Diagnostics for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, was primarily due to an increase increases of $24.0 $115.0 million in material and service costs, $22.1 of which $69.2 million in material and services is due to the Ambry Acquisition, $39.2 million in personnel-related costs, of which $30.7 million is due to the Ambry Acquisition, offset by a decrease of $7.4 million of stock-based compensation expense related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO, $6.0 million IPO in personnel costs, and $4.2 million in cloud expenses. the prior period.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase in Cost of revenues, Genomics Data and applications for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, was primarily due to an increase of $24.0 $14.0 million in material and service cloud costs, $13.6 $4.1 million in royalty fees, $2.9 million of modeling lab related costs, $2.2 million in personnel-related costs, offset by a decrease of $5.4 million of stock-based compensation expense related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO, $7.6 million IPO in personnel costs, $4.2 million in royalty licensing fees, and $1.9 million in cloud expenses. the prior period.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
We define adjusted EBITDA as net income (loss), adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) (benefit from) provision for income taxes, (v) losses on from equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) stock-based compensation expense, (viii) employer payroll tax related to stock-based compensation expense, (ix) acquisition-related expenses, (x) the G-4 Special Payment, (x) Payment (as defined in Note 10 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K), (xi) amortization of deferred other income from our IP License Agreement with SB Tempus, (xi) the settlement of certain historical (xii) franchise taxes related to our IPO, (xiii) other tax expense and potential future disputes, and (xii) acquisition-related expenses. (xiv) loss on debt extinguishment.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
On The Original Credit Agreement was amended on April 25, 2023 and October 11, 2023, we entered into a second amendment to to, among other things, increase the Credit Agreement, which increased the aggregate original principal amount of the Term Loan Facility by an additional $35 million, $85.0 million in the aggregate, less original issue discount of $0.9 million. $2.2 million in the aggregate.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Interest on the Revolving Loans accrues interest at a per annum rate equal to Term SOFR plus 3.75% At all times prior to the termination of the Revolving Commitments, Credit Facility, to the extent that, on any date, the outstanding aggregate principal amount of Revolving Loans Credit Facility is less than the greater of (x) 50.0% of the Revolving Commitments revolving commitments and (y) $50.0 million, the amount of interest payable on account of the Revolving Loans shall be equal to the amount of interest that would be payable had the outstanding principal amount of the Revolving Loans equaled the greater of (x) 50.0% of the Revolving Commitments revolving commitments and (y) $50.0 million (the million, or the Minimum Revolving Interest Amount). Amount.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
If In addition, the Amended Note is outstanding at amendment provides us the option upon maturity date, Google may, at its option, convert to repay up to 50% of the then outstanding principal amount and accrued interest accrued under balance, or the Amended Note into a number of Outstanding Amount, in shares of our Class A common stock equal to the quotient obtained by dividing (1) the Outstanding Amount on the maturity date, by (2) the average of the last trading price on each trading day during the twenty day period ending immediately prior to the maturity date.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.Some of the information contained in this discussion and analysis, including information with respect to our planned investments in our sales and marketing, research and development, and general and administrative functions, includes forward-looking statements that involve risks and uncertainties. 10-K.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEM/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.